Immune‑related adverse events

02/2017

MUDr. Aneta Kyllarová, MUDr. Ondřej Kubeček, MUDr. Jindřich Kopecký, Ph.D.

Klinika onkologie a radioterapie, LF UK a FN Hradec Králové

SUMMARY

Immunotherapy has gradually become a part of standard treatment of selected solid tumours since 2011. The spectrum of malignancies suitable for this treatment modality has been increasing since then. Consequently, the amount of patients treated with immunotherapy has been rising. Despite undeniable efficacy of this modality, we are facing a new spectrum of adverse effect distinct from conventional therapies (radiotherapy, chemotherapy). The aim of this article is to provide a brief review on the most common adverse effects of immunotherapy and their management. We aim to provide physicians, who do not routinely deal with these drugs, with some basic information, so that they are able to manage some minor toxicities or refer the patients to appropriate cancer centre.

KEY WORDS

toxicity, immunotherapy, CTLA-4, PD-1